Saturday, November 21, 2026
19.1 C
Bengaluru

Platforms Are Owning the Patient While Pharma Waits

The future of experimental medicine is not simply a regulatory question. It is a question about who controls access, who pays for treatment, who generates evidence, and who bears the risk.

We spend too much time debating what will happen in healthcare.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img